VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VRDN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/11	19 : 00	Business Wire	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/06/10	21 : 05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/06/07	05 : 01	Business Wire	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/31	21 : 00	Business Wire	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/10	21 : 00	Business Wire	Viridian Therapeutics to Participate in Upcoming May Investor Conferences	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/08	20 : 51	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/08	20 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/08	20 : 00	Business Wire	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/05/03	21 : 00	Business Wire	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/04/29	21 : 00	Business Wire	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/04/05	05 : 01	Business Wire	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/03/07	06 : 01	Business Wire	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/03/05	22 : 00	Business Wire	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/29	06 : 10	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/28	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/28	06 : 01	Business Wire	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/16	22 : 00	Business Wire	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/15	10 : 28	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/15	06 : 08	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/15	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/15	06 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/15	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/14	23 : 01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/08	06 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/02/07	06 : 01	Business Wire	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/01/25	08 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/01/25	07 : 12	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/01/20	07 : 22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/01/20	06 : 32	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:VRDN	Viridian Therapeutics Inc
2024/01/18	12 : 00	Business Wire	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock	NASDAQ:VRDN	Viridian Therapeutics Inc